【Insight_Partners】2024-2030年欧洲基因检测服务市场分析与预测报告_104页_1mb

Europe Genetic Testing Services Market Summary

Core Content

The Europe genetic testing services market is expected to grow significantly from 2022 to 2030, driven by several key factors. The market is segmented by service type, disease, service provider, and country, with comprehensive revenue forecasts and growth analysis provided for each segment.

Key Market Drivers

• Rising Prevalence of Genetic Diseases: Genetic diseases are becoming more common, with a significant portion of the population affected. For example, in the UK, around 15,000 individuals suffer from sickle cell disease, and 270 newborns are diagnosed with it annually. The global prevalence of genetic diseases is estimated to be around 300 million people.
• Increasing Awareness and Acceptance of Personalized Medicines: Personalized medicine, which uses genetic and environmental data to tailor healthcare, is gaining traction. The Human Genome Project (HGP) and decreasing sequencing costs have accelerated the development of this field. France has implemented a national plan for personalized medicine, "Genomic Medicine France 2025," which is expected to position the country as a leader in genomic medicine within a decade.
• Growing Preference for Direct-To-Consumer (DTC) Genetic Testing: DTC genetic testing is becoming increasingly popular due to its accessibility and convenience. Consumers are seeking personalized health insights and early disease detection through these kits, which are often available without a prescription or guidance from a healthcare professional.

Market Restraints

• Social and Ethical Implications of Genetic Testing: There are concerns regarding the potential for stigmatization, discrimination, and psychological consequences due to the knowledge of genetic risks. These issues may deter some individuals from undergoing genetic testing.
• Affordability of Genetic Services: High costs associated with genetic testing services can limit access, especially in developing countries, thereby acting as a restraint on market growth.

Market Opportunities

• Rising Demand for Pharmacogenomics: The integration of genetic testing in pharmacogenomics is creating new opportunities, as it enables the development of personalized therapies and improves drug efficacy and safety.
• Emerging Markets in Developing Countries: There is potential for growth in regions where genetic testing is less adopted, as awareness and accessibility improve.

Future Trends

• Artificial Intelligence-Powered Genetic Testing: AI is expected to revolutionize genetic testing by enhancing data analysis, improving diagnostic accuracy, and enabling faster and more cost-effective testing processes.

Market Segmentation

By Service Type

• Predictive Testing: Focuses on identifying genetic predispositions to diseases.
• Carrier Testing: Detects genetic disorders that can be passed on to offspring.
• Prenatal Testing: Used to screen for genetic abnormalities in fetuses.
• Newborn Screening: Identifies genetic disorders in newborns.
• Others: Includes various other types of genetic testing.

By Disease

• Cancer: A major driver of genetic testing demand due to the importance of early detection and personalized treatment.
• Cardiovascular Diseases: Genetic testing helps in understanding hereditary risk factors.
• Metabolic Diseases: Genetic testing is crucial for diagnosing and managing inherited metabolic conditions.
• Other Diseases: Includes a range of genetic disorders and conditions.

By Service Provider

• Hospital-Based Laboratories: Traditional providers of genetic testing services.
• Diagnostic Laboratories: Specialized in offering a wide range of genetic testing services.
• Others: Includes various other service providers such as research institutions and private testing companies.

Regional Growth Opportunity Analysis

The market is analyzed across key countries in Europe, including the UK, Germany, France, Italy, Spain, and the Rest of Europe. Each country's market is evaluated based on service type, disease, and service provider segments.

Country Analysis

• UK: Expected to maintain a significant market share, with a focus on predictive testing and prenatal testing.
• Germany: Strong market presence with a diverse range of service types and diseases.
• France: Active in the development of personalized medicine and genomic programs.
• Italy: Growing market with increasing adoption of genetic testing services.
• Spain: Exhibiting steady growth in the genetic testing services market.
• Rest of Europe: Projected to experience growth due to increasing awareness and expanding healthcare infrastructure.

Key Players in the Market

• Eurofins Scientific SE: A leading provider of genetic testing services with a broad range of offerings.
• Exact Sciences Corp: Specializes in cancer genetic testing.
• Laboratory Corp of America Holdings: Offers comprehensive genetic testing services.
• 23andMe Holding Co: A prominent player in the DTC genetic testing market.
• Quest Diagnostics Inc.: Provides a wide array of genetic testing services.
• Illumina Inc.: A key player in genetic sequencing technology.
• F. Hoffmann-La Roche Ltd: Involved in various genetic testing and pharmaceutical applications.
• NeoGenomics Inc: Offers genetic testing services with a focus on oncology.
• Centogene AG: Specializes in rare disease testing and research.

Revenue Forecast and Market Size

• Market Size in 2022: $2,778.42 million
• Market Size in 2030: $931.11 million
• CAGR (2022-2030): 14.6%

The market is projected to grow at a compound annual growth rate (CAGR) of 14.6% over the forecast period, driven by increasing demand for genetic testing and advancements in technology.

Research Methodology

The research methodology includes both secondary and primary research. Secondary research involves the use of internal and external sources such as company websites, annual reports, industry journals, and government publications. Primary research is conducted through interviews with industry participants and experts to validate findings and gain deeper insights into market dynamics.

Conclusion

The Europe genetic testing services market is poised for substantial growth, influenced by the rising prevalence of genetic diseases, increased awareness of personalized medicine, and the growing preference for DTC genetic testing. Despite restraints such as social and ethical implications and affordability issues, the market presents significant opportunities, particularly in pharmacogenomics and emerging markets. The integration of artificial intelligence is expected to further enhance the market's potential, making genetic testing more efficient and accessible.